References
- Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines9th edn. Informa Healthcare, London 2007
- National Institute of Clinical Excellence. Guidance on the Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Health Technology Appraisal No 43. Available from URL: www.nice.org.uk, 2002.
- Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E. Benefits and risks of antipsychotic polypharmacy. An evidence based review of the literature. Drug Safety 2008; 31: 7–20
- Waddington J, Youseff H, Kinsella A. Mortality in schizophrenia. antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 1998; 173: 325–329
- Connolly A, Taylor D. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. British Journal of Psychiatry 2008; 193: 161–162
- Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 2002; 159: 567–572